US20010039013A1 - P53-regulated genes - Google Patents
P53-regulated genes Download PDFInfo
- Publication number
- US20010039013A1 US20010039013A1 US09/755,028 US75502801A US2001039013A1 US 20010039013 A1 US20010039013 A1 US 20010039013A1 US 75502801 A US75502801 A US 75502801A US 2001039013 A1 US2001039013 A1 US 2001039013A1
- Authority
- US
- United States
- Prior art keywords
- transcripts
- expression
- translation products
- level
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Definitions
- the invention relates to the area of gene regulation, in particular the area of regulation of genes involved in tumorigenesis.
- P53 is the name of a human tumor suppressor gene and its protein product. About 55 percent of all human cancers from many cell or tissue types suffer mutations in both alleles of the p53 gene. People who have inherited such mutations, will develop cancer over their lifetimes.
- the p53 protein is a transcription factor, which regulates the expression of a large number of genes. High levels of an active wild type p53 protein in a cell cause these genes to be transcribed at a high rate. Elucidation of the functions of some of these “p53-regulated or -inducible genes” informs the art of how the p53 protein protects humans from cancers.
- a method for diagnosing cancer or for determining p53 status in a sample suspected of being neoplastic.
- the level of expression of an RNA transcript or its translation product in a first sample of a first tissue is compared to the level of expression of the transcript or translation product in a second sample of a second tissue.
- the first tissue is suspected of being neoplastic and the second tissue is a normal human tissue.
- the first and second tissue are of the same tissue type.
- the transcript is a transcript of a gene selected from the group consisting of gene numbers 1-8, 10, 12, 14-58, 60-68, and 70-100, as shown in FIG. 1.
- the first sample is categorized as neoplastic or as having a mutant p53 when expression is found to be the same or lower in the first sample than in the second sample.
- a method for diagnosing cancer or for determining p53 status in a sample suspected of being neoplastic.
- the level of expression of an RNA transcript or its translation product in a first sample of a first tissue is compared to the level of expression of the transcript or translation product in a second sample of a second tissue.
- the first tissue is suspected of being neoplastic and the second tissue is a normal human tissue.
- the first and second tissue are of the same tissue type.
- the transcript is a transcript of a gene selected from the group consisting of gene numbers 7-24, and 26-100 as shown in FIG. 2.
- the first sample is categorized as neoplastic or as having a mutant p53 when expression is found to be the same or higher in the first sample than in the second sample.
- Another aspect of the invention is a method of diagnosing cancer or determining p53 status in a sample suspected of being neoplastic.
- the level of expression of at least one RNA transcript or its translation product in a first sample of a first tissue is compared to the level of expression of the transcripts or translation products in a second sample of a second tissue.
- the first tissue is suspected of being neoplastic and the second tissue is a normal human tissue.
- the first and second tissue are of the same tissue type.
- the first group of RNA transcripts consists of transcripts of genes selected from the group of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 as shown in FIG. 1.
- the second group of RNA transcripts consists of transcripts of genes selected from the group consisting of genes numbered 7-24, and 25-100 as shown in FIG. 2.
- the first sample is categorized as neoplastic or as having a mutant p53 when expression of at least one of the first group of RNA transcripts or translation products is found to be the same or lower in the first sample than in the second sample, and expression of at least one of the second group of transcripts or translation products is found to be the same or higher in the first sample than in the second sample.
- a method for evaluating carcinogenicity of an agent.
- a test agent is contacted with a human cell.
- the level of expression of at least one transcript or its translation product is determined in the human cell after contacting with the agent.
- the transcript is of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2.
- An agent which decreases the level of expression of a gene identified in FIG. 1, or an agent which increases the level of expression of a gene identified in FIG. 2 is identified as a potential carcinogen.
- Another aspect of the invention is directed to a method of treating cancer in a patient
- a polynucleotide is administered to cancer cells of a patient.
- the polynucleotide comprises a coding sequence of a gene selected from the group Consists of genes number 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1.
- the cancer cells of the patient harbor a mutant p53 gene. As a result of the administration, the gene is expressed in cells of the cancer.
- Yet another aspect of the invention is directed to a method of treating cancer in a patient.
- An antisense construct comprising at least 12 nucleotides of a coding sequence of a gene selected from the group consisting of genes numbered 7-24, and 26-100 in FIG. 2 is administered to cancer cells of a patient.
- the coding sequence is in 3′ to 5′ orientation with respect to a promoter which controls its expression.
- the cancer cells harbor a mutant p53 gene.
- an antisense RNA is expressed in cells of the cancer.
- a method is provided of screening for drugs useful in the treatment of cancer.
- a cell which harbors a p53 mutation is contacted with a test substance.
- Expression of a transcript or its translation product is monitored.
- the transcript is of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2.
- a test substance is identified as a potential drug for treating cancer if it increases expression of a gene as shown in FIG. 1 or decreases expression of a gene as shown in FIG. 2.
- Another aspect of the invention is a method of screening for drugs useful in the treatment of cancer.
- a tumor cell which overexpresses MDM2 is contacted with a test substance. Expression of a transcript or its translation product is monitored.
- the transcript is of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2.
- a test substance is identified as a potential drug for treating cancer if it increases expression of a gene as shown in FIG. 1 or decreases expression of a gene as shown in FIG. 2.
- Yet another aspect of the invention provides a set of at least two nucleotide probes which hybridize to a set of p53-regulated genes.
- the genes are selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2.
- FIG. 1 is a Table showing genes induced by p53.
- the column headings are as follows.
- “Eb1” denotes the cell line EB1- ⁇ , i.e., a cell line which contains a zinc-inducible p53 gene.
- EB denotes the cell line EB1, a cell line which has a p53 mutant gene that fails to produce or express detectable p53 protein.
- PM denotes the number of perfect match oligonucleotides for a gene which hybridized
- MM denotes the number of mismatch oligonucleotides for a gene which hybridized.
- “Ratio” is the ratio of intensity of EB1- ⁇ to EB1.
- Access number refers to a Genrank accession number. “EST?” if checked indicates that the function of the nucleic acid sequence has not been determined. “SAGE?” if checked indicates that analysis using the SAGE technique also detected this gene as p53-regulated. See http://welchink.welch.jhu.edu/ ⁇ molgen-g/P53-SAGE.HTM.
- FIG. 2 is a Table showing genes repressed by p53. Column headings are the same as in FIG. 1.
- p53 regulates a whole host of genes, increasing and decreasing expression of their mRNA and protein products. These genes have not previously been identified as p53 regulated. In some cases the biological functions of the genes is unknown. However, the now-established regulation by p53 indicates that the genes are involved in progression and arrest of the cell cycle.
- RNA transcript or its translation product can be determined using any techniques known in the art.
- Specific oligonucleotide probes for the relevant genes can be used in hybridization experiments, as is known in the art. Any hybridization format for determining specific RNA levels can be used, including but not limited to Northern blots, slot blots, dot blots, and hybridization to oligonucleotide arrays. Specificity of hybridization can be assessed by varying degrees of stringency of the hybridization conditions.
- comparison of mismatch to perfect match oligonucleotide probes can be used to determine specificity of binding.
- antibodies specific for the protein can be used readily. Again, any format known in the art for measuring specific protein levels can be used, including sandwich assays, ELISAs, immunoprecipitations, and Western blots. Any of monoclonal antibodies, polyclonal antibodies, single chain antibodies, and antibody fragments may be used in such assays. Specificity of immunologic reactions can be assessed using competitor antibodies or proteins, as well as by varying the immunoreaction conditions.
- Monitoring expression product levels involves determining amounts of a specific expression product. Amounts determined need not be absolute amounts, but may be relative amounts determined under different conditions, for example, in the presence and absence of a test compound.
- Probes according to the present invention may be labeled or unlabeled, tethered to another substance or in solution, synthetically made or isolated from nature. Probes can be nucleic adds, either RNA or DNA, which contain naturally occurring nucleotide bases or modified bases. The probes may contain normal nucleotide bonds or peptide bonds. Oligonucleotide probes may be of any length which provides meaningful specificity of hybridization. Thus probes may be as small as 10 nucleotides, and preferably they are between 12 and 30 nucleotides in length.
- oligonucleotide probes may be significantly longer, in the range of 30 to 100 nucleotides, 100 to 500 nucleotides or 500 to 2000 nucleotides.
- Probes may be attached to polymers, either soluble or non-soluble. Probes may be attached or bonded to solid substrates such as filters, sheets, chips, slides, and beads.
- High density arrays are particularly useful for monitoring the expression control at the transcriptional, RNA processing and degradation level.
- the fabrication and application of high density arrays in gene expression monitoring have been disclosed previously in, for example, WO 97/10365, WO 92/10588, U.S. application Ser. No. 08/772,376 filed Dec. 23, 1996; Ser. No. 08/529,115 filed on Sep. 15, 1995; Ser. No. 08/168,904 filed Dec. 15, 1993; Ser. No. 07/624,114 filed on Dec. 6, 1990, Ser. No. 07/362,901 filed Jun. 7, 1990, all incorporated herein for all purposed by reference.
- high density oligonucleotide arrays are synthesized using methods such as the Very Large Scale Immobilized Polymer Synthesis (VLSIPS) disclosed in U.S. Pat. No. 5,445,934 incorporated herein for all purposes by reference.
- VLSIPS Very Large Scale Immobilized Polymer Synthesis
- Each oligonucleotide occupies a known location on a substrate.
- a nucleic acid target sample is hybridized with a high density array of oligonucleotides and then the amount of target nucleic acids hybridized to each probe in the array is quantified.
- One preferred quantifying method is to use confocal microscope and fluorescent labels.
- the GeneChip® system (Affymetrix, Santa Clara, Calif.) is particularly suitable for quantifying the hybridization; however, it will be apparent to those of skill in the art that any similar systems or other effectively equivalent detection methods can also be used.
- Tissue samples which can be tested according to the present invention are any which are derived from a patient, whether human, other domestic animal, or veterinary animal. Vertebrate animals are preferred, such as mice, humans, horses, cows, dogs, and cats, although any organism for which p53 status can be determined may be used.
- the form of the samples may be any which are routinely used in the art for determining the amounts of specific proteins or mRNA molecules.
- the samples may be fixed or unfixed, homogenized, lysed, cryopreserved, etc. It is most desirable that matched tissue samples be used as controls. Thus, for example, a suspected colorectal cancer tissue will be compared to a normal colorectal epithelial tissue.
- FIGS. 1 and 2 below show genes which are induced by p53 and repressed by p53, respectively.
- Genes which are identified with a check in the column headed “SAGE” are those which are believed to be previously identified as p53-regulated.
- Genes which are not checked are believed to be previously unknown as p53-regulated genes.
- Genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1, and genes numbered 7-24, and 26-100 in FIG. 2, are believed to be such previously unknown p53-regulated genes.
- While assaying expression of any single one of the genes identified as p53-regulated may be useful for diagnosis and assays, it may be desirable to use larger sets to confirm the global cellular effects observed. In this regard, it may be desirable to assay for at least 2, 5, 10, 20, 30, 32, 50, 70, or 77 genes of one or both categories of regulation. It may be useful to use both induced and repressed genes to get such a global snapshot of gene regulation.
- oligonucleotide probes for RNA transcripts are attached to solid supports.
- Such supports are preferably arrays where nucleic acid molecules are attached to the substrate in predetermined positions.
- the nucleic acid molecules are synthesized on the substrate.
- the nucleic acid molecules are applied to the solid support after synthesis or isolation.
- Test samples for mRNA are typically harvested from the tissue samples and may be used directly or processed as follows.
- the sample mRNA is reverse transcribed using reverse transcriptase to form cDNA.
- a promoter is ligated to the cDNA at its 5′, 3′, or both ends. (5′ and 3′ refer to orientation on the coding strand of DNA.) If two promoters are used on one cDNA they can be the same or different.
- the cDNA is then used as a template to transcribe in vitro to form test mRNA.
- the test RNA can then be used to hybridize to nucleic acid molecules or probes, preferably on a solid support, more preferably on an oligonucleotide array. These processing steps are well known in the art.
- the regulated genes discovered here can form the basis of a carcinogenicity test.
- Test agents are evaluated to see if their effects on human cells mimic the effects of loss of p53.
- the agents are in essence being evaluated for the ability to induce a p53 mutation) or a mutation in another gene which is in the same regulatory pathway, or a non-genetic effect which mimics p53 loss.
- Test agents which are found to have at least some of the same constellation of effects as p53 loss on the regulation of the genes identified herein to be p53-regulated are identified as potential carcinogens. Any single gene identified can be used, as can at least 2, 5, 10, 20, 30, 32, 40, 50, 70, 90, 100, 125, or 145 of the genes identified herein.
- the genes identified herein as p53-induced can be delivered therapeutically to cancer cells.
- Antisense constructs of the genes identified herein as p53-repressed can be delivered therapeutically to cancer cells.
- the goal of such therapy is to retard the growth rate of the cancer cells.
- Expression of the sense molecules and their translation products or expression of the antisense mRNA molecules has the effect of inhibiting the growth rate of cancer cells or inducing apoptosis (a radical reduction in the growth rate of a cell).
- Sense nucleic acid molecules are preferably delivered in constructs wherein a promoter is operatively linked to the coding sequence at the 5′-end and initiates transcription of the coding sequence.
- Anti-sense constructs contain a promoter operatively linked to the coding sequence at the 3′-end such that upon initiation of transcription at the promoter an RNA molecule is transcribed which is the complementary strand from the native mRNA molecule of the gene.
- GDVS Gene delivery vehicles
- a polynucleotide sequence of the invention can be administered either locally or systemically in a GDV.
- GDV Gene delivery vehicles
- These constructs can utilize viral or non-viral vector approaches in in vivo or ex vivo modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence in vivo can be either constituted or regulated.
- the invention includes gene delivery vehicles capable of expressing the contemplated polynucleotides.
- the gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vectors.
- the viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, togavirus viral vector. See generally, Jolly, Cancer Gene Therapy 1:51-64 (1994); Kimura, Human Gene Therapy 5:845-852 (1994), Connelly, Human Gene Therapy 6:185-193 (1995), and Kaplitt, Nature Genetics 6:148-153 (1994).
- Delivery of the gene therapy constructs of this invention into cells is not limited to the above mentioned viral vectors.
- Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see Curiel, Hum Gene Ther 3:147-154 (1992) ligand linked DNA, for example, see Wu, J. Biol. Chem 264:16985-16987 (1989), eucaryotic cell delivery vehicles cells, for example see U.S. Ser. No. 08/240,030, filed May 9, 1994, and U.S. Ser. No. 08/404,796, deposition of photopolymerized hydrogel materials, handheld gene transfer particle gun, as described in U.S. Pat.
- the sequence can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described in Wu and Wu, J. Biol. Chem 262:4429-4432 (1987), insulin as described in Hucked, Biochem. Pharmacol. 40:253-263 (1990), galactose as described in Plank, Bioconjugate Chem 3:533-539 (1992), lactose or transferrin. Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in PCT Patent Publication No.
- Drugs useful in the treatment of cancer can be screened and identified using the p53-regulated genes disclosed herein.
- Cells of two types can be contacted with test substances.
- the cells may not carry a wild-type p53 allele or the cells may overexpress the MDM2 gene product.
- MDM2 sequesters wild-type p53. Therefore MDM2-overexpressing cells mimic cells which are genetically deficient for p53.
- Expression of one or more of the p53-regulated genes of the present invention is monitored in the presence of the test substance.
- a test substance which mimics one or more of the regulatory effects of p53 on the p53-regulated genes is a potential therapeutic agent for treating cancer. Such agents can be subsequently tested in any number of other assays to determine their ultimate usefulness as a drug.
- oligonucleotide probes are provided.
- the probes are exclusively perfectly matched probes to the genes.
- mismatch probes having less than 5% mismatched nucleotides can be used.
- the probes hybridize to the p53-regulated genes disclosed herein in FIGS. 1 and 2. Particularly useful genes are those numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1, and those numbered 7-24, and 26-100 in FIG. 2. It is preferred that all of the oligonucleotide probes hybridize to p53-regulated genes, although it is permissible to have probes for other genes present which are not p53 regulated.
- the probes for other genes comprise less than 50% of the probes, and more preferably comprise less than 25%, 15%, 10%, 5%, 2%, or 1%.
- the sets of p53 regulated genes may comprise at least five, ten, fifteen, twenty, twenty-five, thirty, fifty, seventy-five, 100, or 140 oligonucleotide probes p53-regulated genes, as disclosed herein.
- the probes may be attached to a polymer, soluble or insoluble, naturally occurring or synthetic.
- the probes may be attached to a solid support, in a gel matrix, or in solution.
- the probes may be individually packaged and contained within a single container, or may be mixed in one or more mixtures.
- the probes are arrayed on a solid support.
- Eb-1 cells were derived from a human colon carcinoma and these cells have a p53 mutant gene that fails to produce or express detectable p53 protein.
- a p53 wild-type gene was inserted into these cells under the regulation of a metallothionein (MT) promoter. In the presence of zinc, this promoter expresses the p53 gene but in the absence (or low levels) of zinc, little or no p53 mRNA or protein are produced. Thus, p53 mRNA and protein are zinc-inducible and the p53-regulated genes are similarly induced by the addition of zinc.
- the Eb-1 cells original cell line
- Eb1 and Eb1 cells with the MT-p53 inducible gene are termed Eb-1 ( ⁇ ).
- Eb-1 cells and Eb-1 (alpha) cells were grown in culture and either left untreated or exposed to zinc. Four hours and ten hours after the addition of zinc, these cells were harvested for analysis.
- RNA was hybridized to a chip that contains deoxyoligonucleotide sequence (25 in length) that derive from a database of 6,800 known genes or EST sequences. There is a 20-fold redundancy for each gene or EST sequence and for each perfect sequence match, a mismatched sequence (one base different in the middle of the sequence of 25 nucleotides).
- the chips After a short hybridization, that measures the rate (amount) of fluorescent probe hybridized to each set of 20 oligonucleotide sequences, the chips are washed and read by a digital confocal microscope to quantitate the intensity of the fluorescent readout. Gene expression or mRNA concentration is measured by changes in the fluorescent readout for probe pairs. The specificity of the measurements is given by the ratio of hybridization to a perfect sequence matched probe compared with the hybridization to a mismatched probe.
- Eb-1 ( ⁇ ) cells were treated with zinc or left untreated and at four or ten hours, the cells were harvested.
- RNA was prepared and processed as described above. The hybridization to the 6,800 different oligonucleotide sequences on the chip (each cDNA had a twenty-fold sequence redundancy covering different sequences in the cDNA) was carried out and the analysis of the data was done by an algorithm.
- FIG. 1 lists the genes which are induced by p53 and FIG. 2 lists the genes which are repressed by p53.
Abstract
Many genes are identified as being p53-regulated which were not heretofore known to be p53-regulated. This includes both genes whose expression is induced and genes whose expression is repressed by the expression of wild-type p53. Monitoring expression of these genes is used to provide indications of p53 status in a cell. Such monitoring can also be used to screen for useful anti cancer therapeutics, as well as for substances which are carcinogenic. Defects in p53 can be bypassed by supplying p53 induced genes to cells. Defects in p53 can also be bypassed by supplying antisense constructs to p53-repressed genes.
Description
- The invention relates to the area of gene regulation, in particular the area of regulation of genes involved in tumorigenesis.
- P53 is the name of a human tumor suppressor gene and its protein product. About 55 percent of all human cancers from many cell or tissue types suffer mutations in both alleles of the p53 gene. People who have inherited such mutations, will develop cancer over their lifetimes.
- The p53 protein is a transcription factor, which regulates the expression of a large number of genes. High levels of an active wild type p53 protein in a cell cause these genes to be transcribed at a high rate. Elucidation of the functions of some of these “p53-regulated or -inducible genes” informs the art of how the p53 protein protects humans from cancers.
- There is a need in the art to discover p53-inducible genes and their functions, so that we may have a chance to circumvent the effects of p53 mutations in cancer, by activating the p53-inducible genes and repressing the p53-repressible genes, so as to arrest the cancer's growth. Thus, the elucidation of such p53-regulated genes provides useful and valuable information.
- In one embodiment, a method is provided for diagnosing cancer or for determining p53 status in a sample suspected of being neoplastic. The level of expression of an RNA transcript or its translation product in a first sample of a first tissue is compared to the level of expression of the transcript or translation product in a second sample of a second tissue. The first tissue is suspected of being neoplastic and the second tissue is a normal human tissue. The first and second tissue are of the same tissue type. The transcript is a transcript of a gene selected from the group consisting of gene numbers 1-8, 10, 12, 14-58, 60-68, and 70-100, as shown in FIG. 1. The first sample is categorized as neoplastic or as having a mutant p53 when expression is found to be the same or lower in the first sample than in the second sample.
- According to another embodiment a method is provided for diagnosing cancer or for determining p53 status in a sample suspected of being neoplastic. The level of expression of an RNA transcript or its translation product in a first sample of a first tissue is compared to the level of expression of the transcript or translation product in a second sample of a second tissue. The first tissue is suspected of being neoplastic and the second tissue is a normal human tissue. The first and second tissue are of the same tissue type. The transcript is a transcript of a gene selected from the group consisting of gene numbers 7-24, and 26-100 as shown in FIG. 2. The first sample is categorized as neoplastic or as having a mutant p53 when expression is found to be the same or higher in the first sample than in the second sample.
- Another aspect of the invention is a method of diagnosing cancer or determining p53 status in a sample suspected of being neoplastic. The level of expression of at least one RNA transcript or its translation product in a first sample of a first tissue is compared to the level of expression of the transcripts or translation products in a second sample of a second tissue. The first tissue is suspected of being neoplastic and the second tissue is a normal human tissue. The first and second tissue are of the same tissue type. The first group of RNA transcripts consists of transcripts of genes selected from the group of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 as shown in FIG. 1. The second group of RNA transcripts consists of transcripts of genes selected from the group consisting of genes numbered 7-24, and 25-100 as shown in FIG. 2. The first sample is categorized as neoplastic or as having a mutant p53 when expression of at least one of the first group of RNA transcripts or translation products is found to be the same or lower in the first sample than in the second sample, and expression of at least one of the second group of transcripts or translation products is found to be the same or higher in the first sample than in the second sample.
- According to another aspect of the invention a method is provided for evaluating carcinogenicity of an agent. A test agent is contacted with a human cell. The level of expression of at least one transcript or its translation product is determined in the human cell after contacting with the agent. The transcript is of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2. An agent which decreases the level of expression of a gene identified in FIG. 1, or an agent which increases the level of expression of a gene identified in FIG. 2 is identified as a potential carcinogen.
- Another aspect of the invention is directed to a method of treating cancer in a patient A polynucleotide is administered to cancer cells of a patient. The polynucleotide comprises a coding sequence of a gene selected from the group Consists of genes number 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1. The cancer cells of the patient harbor a mutant p53 gene. As a result of the administration, the gene is expressed in cells of the cancer.
- Yet another aspect of the invention is directed to a method of treating cancer in a patient. An antisense construct comprising at least 12 nucleotides of a coding sequence of a gene selected from the group consisting of genes numbered 7-24, and 26-100 in FIG. 2 is administered to cancer cells of a patient. The coding sequence is in 3′ to 5′ orientation with respect to a promoter which controls its expression. The cancer cells harbor a mutant p53 gene. As a result of the administration an antisense RNA is expressed in cells of the cancer.
- According to still another aspect of the invention a method is provided of screening for drugs useful in the treatment of cancer. A cell which harbors a p53 mutation is contacted with a test substance. Expression of a transcript or its translation product is monitored. The transcript is of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2. A test substance is identified as a potential drug for treating cancer if it increases expression of a gene as shown in FIG. 1 or decreases expression of a gene as shown in FIG. 2.
- Another aspect of the invention is a method of screening for drugs useful in the treatment of cancer. A tumor cell which overexpresses MDM2 is contacted with a test substance. Expression of a transcript or its translation product is monitored. The transcript is of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2. A test substance is identified as a potential drug for treating cancer if it increases expression of a gene as shown in FIG. 1 or decreases expression of a gene as shown in FIG. 2.
- Yet another aspect of the invention provides a set of at least two nucleotide probes which hybridize to a set of p53-regulated genes. The genes are selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2.
- These and other embodiments of the invention provide the art with methods for diagnosis, treatment and drug discovery for cancers. In addition, it provides a convenient and rapid carcinogenicity test.
- FIG. 1 is a Table showing genes induced by p53. The column headings are as follows. “Eb1” denotes the cell line EB1-α, i.e., a cell line which contains a zinc-inducible p53 gene. “EB” denotes the cell line EB1, a cell line which has a p53 mutant gene that fails to produce or express detectable p53 protein. “PM” denotes the number of perfect match oligonucleotides for a gene which hybridized and “MM” denotes the number of mismatch oligonucleotides for a gene which hybridized. “Ratio” is the ratio of intensity of EB1-α to EB1. “Accession number” refers to a Genrank accession number. “EST?” if checked indicates that the function of the nucleic acid sequence has not been determined. “SAGE?” if checked indicates that analysis using the SAGE technique also detected this gene as p53-regulated. See http://welchink.welch.jhu.edu/˜molgen-g/P53-SAGE.HTM.
- FIG. 2 is a Table showing genes repressed by p53. Column headings are the same as in FIG. 1.
- It is a discovery of the present inventors that p53 regulates a whole host of genes, increasing and decreasing expression of their mRNA and protein products. These genes have not previously been identified as p53 regulated. In some cases the biological functions of the genes is unknown. However, the now-established regulation by p53 indicates that the genes are involved in progression and arrest of the cell cycle.
- A sampling of 6800 human genes were tested for the effects of p53 expression on their expression. Such a massive screening permits the identification of many genes which were heretofore not known to be p53 regulated.
- Genetic status of p53 alleles (mutant or wild-type) has been shown to correlate well with a neoplastic state. Thus diagnosis can be provided based on the status of p53 alleles of cells. The level of expression of an RNA transcript or its translation product can be determined using any techniques known in the art. Specific oligonucleotide probes for the relevant genes can be used in hybridization experiments, as is known in the art. Any hybridization format for determining specific RNA levels can be used, including but not limited to Northern blots, slot blots, dot blots, and hybridization to oligonucleotide arrays. Specificity of hybridization can be assessed by varying degrees of stringency of the hybridization conditions. In addition, comparison of mismatch to perfect match oligonucleotide probes can be used to determine specificity of binding. To assess specific translation product (protein) expression levels, antibodies specific for the protein can be used readily. Again, any format known in the art for measuring specific protein levels can be used, including sandwich assays, ELISAs, immunoprecipitations, and Western blots. Any of monoclonal antibodies, polyclonal antibodies, single chain antibodies, and antibody fragments may be used in such assays. Specificity of immunologic reactions can be assessed using competitor antibodies or proteins, as well as by varying the immunoreaction conditions. Monitoring expression product levels involves determining amounts of a specific expression product. Amounts determined need not be absolute amounts, but may be relative amounts determined under different conditions, for example, in the presence and absence of a test compound.
- Probes according to the present invention may be labeled or unlabeled, tethered to another substance or in solution, synthetically made or isolated from nature. Probes can be nucleic adds, either RNA or DNA, which contain naturally occurring nucleotide bases or modified bases. The probes may contain normal nucleotide bonds or peptide bonds. Oligonucleotide probes may be of any length which provides meaningful specificity of hybridization. Thus probes may be as small as 10 nucleotides, and preferably they are between 12 and 30 nucleotides in length. However, oligonucleotide probes may be significantly longer, in the range of 30 to 100 nucleotides, 100 to 500 nucleotides or 500 to 2000 nucleotides. Probes may be attached to polymers, either soluble or non-soluble. Probes may be attached or bonded to solid substrates such as filters, sheets, chips, slides, and beads.
- High density arrays are particularly useful for monitoring the expression control at the transcriptional, RNA processing and degradation level. The fabrication and application of high density arrays in gene expression monitoring have been disclosed previously in, for example, WO 97/10365, WO 92/10588, U.S. application Ser. No. 08/772,376 filed Dec. 23, 1996; Ser. No. 08/529,115 filed on Sep. 15, 1995; Ser. No. 08/168,904 filed Dec. 15, 1993; Ser. No. 07/624,114 filed on Dec. 6, 1990, Ser. No. 07/362,901 filed Jun. 7, 1990, all incorporated herein for all purposed by reference. In some embodiments using high density arrays, high density oligonucleotide arrays are synthesized using methods such as the Very Large Scale Immobilized Polymer Synthesis (VLSIPS) disclosed in U.S. Pat. No. 5,445,934 incorporated herein for all purposes by reference. Each oligonucleotide occupies a known location on a substrate. A nucleic acid target sample is hybridized with a high density array of oligonucleotides and then the amount of target nucleic acids hybridized to each probe in the array is quantified. One preferred quantifying method is to use confocal microscope and fluorescent labels. The GeneChip® system (Affymetrix, Santa Clara, Calif.) is particularly suitable for quantifying the hybridization; however, it will be apparent to those of skill in the art that any similar systems or other effectively equivalent detection methods can also be used.
- Tissue samples which can be tested according to the present invention are any which are derived from a patient, whether human, other domestic animal, or veterinary animal. Vertebrate animals are preferred, such as mice, humans, horses, cows, dogs, and cats, although any organism for which p53 status can be determined may be used. The form of the samples may be any which are routinely used in the art for determining the amounts of specific proteins or mRNA molecules. The samples may be fixed or unfixed, homogenized, lysed, cryopreserved, etc. It is most desirable that matched tissue samples be used as controls. Thus, for example, a suspected colorectal cancer tissue will be compared to a normal colorectal epithelial tissue.
- FIGS. 1 and 2 below show genes which are induced by p53 and repressed by p53, respectively. Genes which are identified with a check in the column headed “SAGE” are those which are believed to be previously identified as p53-regulated. Genes which are not checked are believed to be previously unknown as p53-regulated genes. Genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1, and genes numbered 7-24, and 26-100 in FIG. 2, are believed to be such previously unknown p53-regulated genes.
- While assaying expression of any single one of the genes identified as p53-regulated may be useful for diagnosis and assays, it may be desirable to use larger sets to confirm the global cellular effects observed. In this regard, it may be desirable to assay for at least 2, 5, 10, 20, 30, 32, 50, 70, or 77 genes of one or both categories of regulation. It may be useful to use both induced and repressed genes to get such a global snapshot of gene regulation.
- In a particularly preferred embodiment, oligonucleotide probes for RNA transcripts are attached to solid supports. Such supports are preferably arrays where nucleic acid molecules are attached to the substrate in predetermined positions. In one particular embodiment, the nucleic acid molecules are synthesized on the substrate. In another embodiment the nucleic acid molecules are applied to the solid support after synthesis or isolation.
- Test samples for mRNA are typically harvested from the tissue samples and may be used directly or processed as follows. The sample mRNA is reverse transcribed using reverse transcriptase to form cDNA. A promoter is ligated to the cDNA at its 5′, 3′, or both ends. (5′ and 3′ refer to orientation on the coding strand of DNA.) If two promoters are used on one cDNA they can be the same or different. The cDNA is then used as a template to transcribe in vitro to form test mRNA. The test RNA can then be used to hybridize to nucleic acid molecules or probes, preferably on a solid support, more preferably on an oligonucleotide array. These processing steps are well known in the art.
- The regulated genes discovered here can form the basis of a carcinogenicity test. Test agents are evaluated to see if their effects on human cells mimic the effects of loss of p53. Thus the agents are in essence being evaluated for the ability to induce a p53 mutation) or a mutation in another gene which is in the same regulatory pathway, or a non-genetic effect which mimics p53 loss. Test agents which are found to have at least some of the same constellation of effects as p53 loss on the regulation of the genes identified herein to be p53-regulated, are identified as potential carcinogens. Any single gene identified can be used, as can at least 2, 5, 10, 20, 30, 32, 40, 50, 70, 90, 100, 125, or 145 of the genes identified herein.
- The genes identified herein as p53-induced can be delivered therapeutically to cancer cells. Antisense constructs of the genes identified herein as p53-repressed can be delivered therapeutically to cancer cells. The goal of such therapy is to retard the growth rate of the cancer cells. Expression of the sense molecules and their translation products or expression of the antisense mRNA molecules has the effect of inhibiting the growth rate of cancer cells or inducing apoptosis (a radical reduction in the growth rate of a cell). Sense nucleic acid molecules are preferably delivered in constructs wherein a promoter is operatively linked to the coding sequence at the 5′-end and initiates transcription of the coding sequence. Anti-sense constructs contain a promoter operatively linked to the coding sequence at the 3′-end such that upon initiation of transcription at the promoter an RNA molecule is transcribed which is the complementary strand from the native mRNA molecule of the gene.
- Delivery of nucleic acid molecules can be accomplished by many means known in the art. Gene delivery vehicles (GDVS) are available for delivery of polynucleotides to cells, tissue, or to a the mammal for expression. For example, a polynucleotide sequence of the invention can be administered either locally or systemically in a GDV. These constructs can utilize viral or non-viral vector approaches in in vivo or ex vivo modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence in vivo can be either constituted or regulated. The invention includes gene delivery vehicles capable of expressing the contemplated polynucleotides. The gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vectors. The viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, togavirus viral vector. See generally, Jolly, Cancer Gene Therapy 1:51-64 (1994); Kimura, Human Gene Therapy 5:845-852 (1994), Connelly, Human Gene Therapy 6:185-193 (1995), and Kaplitt, Nature Genetics 6:148-153 (1994).
- Delivery of the gene therapy constructs of this invention into cells is not limited to the above mentioned viral vectors. Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see Curiel, Hum Gene Ther 3:147-154 (1992) ligand linked DNA, for example, see Wu, J. Biol. Chem 264:16985-16987 (1989), eucaryotic cell delivery vehicles cells, for example see U.S. Ser. No. 08/240,030, filed May 9, 1994, and U.S. Ser. No. 08/404,796, deposition of photopolymerized hydrogel materials, handheld gene transfer particle gun, as described in U.S. Pat. No. 5,149,655, ionizing radiation as described in U.S. Pat. No. 5,206,152 and in PCT Patent Publication No. WO 92/11033, nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip, Mol. Cell. Biol. 14:2411-2418 (1994) and in Woffendin, Proc. Natl. Acad Sci. 91:1581-585 (1994). Particle mediated gene transfer may be employed, for example see U.S. provisional application Ser. No. 60/023,867. Briefly, the sequence can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described in Wu and Wu, J. Biol. Chem 262:4429-4432 (1987), insulin as described in Hucked, Biochem. Pharmacol. 40:253-263 (1990), galactose as described in Plank, Bioconjugate Chem 3:533-539 (1992), lactose or transferrin. Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in PCT Patent Publication No. WO 90/11092 and U.S. Pat. No. 5,580,859. Uptake efficiency may be improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm. Liposomes that can act as gene delivery vehicles are described in U.S. Pat. No. 5,422,120, PCT Patent Publication Nos. WO 95/13796, WO 94/23697, and WO 91/144445, and EP No. 524,968.
- Drugs useful in the treatment of cancer can be screened and identified using the p53-regulated genes disclosed herein. Cells of two types can be contacted with test substances. The cells may not carry a wild-type p53 allele or the cells may overexpress the MDM2 gene product. MDM2 sequesters wild-type p53. Therefore MDM2-overexpressing cells mimic cells which are genetically deficient for p53. Expression of one or more of the p53-regulated genes of the present invention is monitored in the presence of the test substance. A test substance which mimics one or more of the regulatory effects of p53 on the p53-regulated genes is a potential therapeutic agent for treating cancer. Such agents can be subsequently tested in any number of other assays to determine their ultimate usefulness as a drug.
- Sets of at least two oligonucleotide probes are provided. Preferably the probes are exclusively perfectly matched probes to the genes. However, mismatch probes having less than 5% mismatched nucleotides can be used. The probes hybridize to the p53-regulated genes disclosed herein in FIGS. 1 and 2. Particularly useful genes are those numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1, and those numbered 7-24, and 26-100 in FIG. 2. It is preferred that all of the oligonucleotide probes hybridize to p53-regulated genes, although it is permissible to have probes for other genes present which are not p53 regulated. Preferably the probes for other genes comprise less than 50% of the probes, and more preferably comprise less than 25%, 15%, 10%, 5%, 2%, or 1%. The sets of p53 regulated genes may comprise at least five, ten, fifteen, twenty, twenty-five, thirty, fifty, seventy-five, 100, or 140 oligonucleotide probes p53-regulated genes, as disclosed herein. The probes may be attached to a polymer, soluble or insoluble, naturally occurring or synthetic. The probes may be attached to a solid support, in a gel matrix, or in solution. The probes may be individually packaged and contained within a single container, or may be mixed in one or more mixtures. Preferably the probes are arrayed on a solid support.
- The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention. The following methods were used in the examples reported below.
- Eb-1 cells were derived from a human colon carcinoma and these cells have a p53 mutant gene that fails to produce or express detectable p53 protein. A p53 wild-type gene was inserted into these cells under the regulation of a metallothionein (MT) promoter. In the presence of zinc, this promoter expresses the p53 gene but in the absence (or low levels) of zinc, little or no p53 mRNA or protein are produced. Thus, p53 mRNA and protein are zinc-inducible and the p53-regulated genes are similarly induced by the addition of zinc. The Eb-1 cells (original cell line) without a p53 inducible wild-type gene are called Eb1 and Eb1 cells with the MT-p53 inducible gene are termed Eb-1 (α).
- Eb-1 cells and Eb-1 (alpha) cells were grown in culture and either left untreated or exposed to zinc. Four hours and ten hours after the addition of zinc, these cells were harvested for analysis.
- The messenger RNA was extracted from these cells and purified. An oligo-dT primer was used to produce a reverse transcriptase copy of the mRNA and then, an oligonucleotide linker was ligated to the end of the cDNA where the linker has a T-7 promoter sequence incorporated into it. All of the cDNAs were cloned into vectors, which were then employed to make mRNA copies in vitro using the T-7 RNA polymerase and fluorescent biotinylated nucleotides. The RNA products were hydrolyzed to an average size of 50 nucleotides in length.
- The hydrolyzed RNA was hybridized to a chip that contains deoxyoligonucleotide sequence (25 in length) that derive from a database of 6,800 known genes or EST sequences. There is a 20-fold redundancy for each gene or EST sequence and for each perfect sequence match, a mismatched sequence (one base different in the middle of the sequence of 25 nucleotides).
- After a short hybridization, that measures the rate (amount) of fluorescent probe hybridized to each set of 20 oligonucleotide sequences, the chips are washed and read by a digital confocal microscope to quantitate the intensity of the fluorescent readout. Gene expression or mRNA concentration is measured by changes in the fluorescent readout for probe pairs. The specificity of the measurements is given by the ratio of hybridization to a perfect sequence matched probe compared with the hybridization to a mismatched probe.
- For this experiment a control was run; Eb-1 cells treated or untreated with zinc. Here no p53 cDNA was present so the only variable was the exposure of the cells to zinc. Out of all the genes or sequences tested in these cells (6,800), only six changed their gene expression patterns in response to added zinc and five (1-5) of these six genes are under the control of zinc and cadmium inducible promoters. This experiment serves as an excellent control for the p53 regulation of genes.
- For the experiment, Eb-1 (α) cells were treated with zinc or left untreated and at four or ten hours, the cells were harvested. RNA was prepared and processed as described above. The hybridization to the 6,800 different oligonucleotide sequences on the chip (each cDNA had a twenty-fold sequence redundancy covering different sequences in the cDNA) was carried out and the analysis of the data was done by an algorithm. The following criteria were employed to accept a gene as p53-inducible or repressed by p53: (1) the relative intensity of the mRNA hybridization level of an induced gene or a decrease with a repressed gene, was above 160 relative units; this has been shown to be a reproducible level with minimal statistical fluctuations; (2) the fraction of probe pairs (matched hybridized and mismatch not hybridized) had to be 0.85 or greater (17 out of 20 perfect matches); (3) the ratio of induction by p53 or repression by p53, when comparing cellular RNA from Eb-1 zinc-induced cells, was five-fold or greater. Thus, only genes whose mRNA levels increased five-fold or decreased five-fold from a high baseline are reported by this analysis.
- Of 6,800 cDNAs detectable on the chip, 70 genes were induced by p53 and 77 were repressed by p53. Once again, there were excellent positive controls in this experiment. The known p53 inducible genes such as p21-WAF-1, IGF-BP-3, MDM-2, GAD-45, as well as some recently reported 53 inducible genes (PIGS) were detected by this chip hybridization. Similarly, a repressed gene, MAP-4 previously reported in the literature was repressed after p53 induction in Eb-1(α) cells as detected in this experiment.
- FIG. 1 lists the genes which are induced by p53 and FIG. 2 lists the genes which are repressed by p53.
Claims (66)
1. A method of diagnosing cancer or determining p53 status in a sample suspected of being neoplastic, comprising the steps of:
comparing the level of expression of an RNA transcript or its translation product in a first sample of a first tissue to the level of expression of the transcript or translation product in a second sample of a second tissue, wherein the first tissue is suspected of being neoplastic and the second tissue is a normal human tissue, wherein the first and second tissue are of the same tissue type, and wherein the transcript is a transcript of a gene selected from the group consisting of gene numbers 1-8, 10, 12, 14-58, 60-68, and 70-100, as shown in FIG. 1;
categorizing the first sample as neoplastic or as having a mutant p53 when expression is found to be the same or lower in the first sample than in the second sample.
2. A method of diagnosing cancer or determining p53 status in a sample suspected of being neoplastic, comprising the steps of:
comparing the level of expression of an RNA transcript or its translation product in a first sample of a first tissue to the level of expression of the transcript or translation product in a second sample of a second tissue, wherein the first tissue is suspected of being neoplastic and the second tissue is a normal human tissue, wherein the first and second tissue are of the same tissue type, and wherein the transcript is a transcript of a gene selected from the group consisting of gene numbers 7-24, and 26-100 as shown in FIG. 2;
categorizing the first sample as neoplastic or as having a mutant p53 when expression is found to be the same or higher in the first sample than in the second sample.
3. The method of wherein a comparison of at least two of the transcripts or translation products is performed.
claim 1
4. The method of wherein a comparison of at least two of the transcripts or translation products is performed.
claim 2
5. The method of wherein a comparison of at least five of the transcripts or translation products is performed.
claim 1
6. The method of wherein a comparison of at least five of the transcripts or translation products is performed.
claim 2
7. The method of wherein a comparison of at least ten of the transcripts or translation products is performed.
claim 1
8. The method of wherein a comparison of at least ten of the transcripts or translation products is performed.
claim 2
9. The method of wherein a comparison of at least twenty of the transcripts or translation products is performed.
claim 1
10. The method of wherein a comparison of at least twenty of the transcripts or translation products is performed.
claim 2
11. The method of wherein a comparison of at least 32 of the transcripts or translation products is performed.
claim 1
12. The method of wherein a comparison of at least 32 of the transcripts or translation products is performed.
claim 2
13. The method of wherein a comparison of at least fifty of the transcripts or translation products is performed.
claim 1
14. The method of wherein a comparison of at least fifty of the transcripts or translation products is performed.
claim 2
15. The method of wherein a comparison of 70 of the transcripts or translation products is performed.
claim 1
16. The method of wherein a comparison of 77 of the transcripts or translation products is performed.
claim 2
17. A method of diagnosing cancer or determining p53 status in a sample suspected of being neoplastic, comprising the steps of:
comparing the level of expression of at least one RNA transcript or its translation product in a first sample of a first tissue to the level of expression of the transcripts or translation products in a second sample of a second tissue, wherein the first tissue is suspected of being neoplastic and the second tissue is a normal human tissue, wherein the first and second tissue are of the same tissue type, and wherein the first group of RNA transcripts consists of transcripts of genes selected from the group of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 as shown in FIG. 1 and wherein the second group of RNA transcripts consists of transcripts of genes selected from the group consisting of genes numbered 7-24, and 25-100 as shown in FIG. 2;
categorizing the first sample as neoplastic or as having a mutant p53 when expression of at least one of the first group of RNA transcripts or translation products is found to be the same or lower in the first sample than in the second sample, and expression of at least one of the second group of transcripts or translation products is found to be the same or higher in the first sample than in the second sample.
18. The method of wherein a comparison of at least two of the transcripts or translation products in each group of transcripts or translation products is performed.
claim 17
19. The method of wherein a comparison of at least five of the transcripts or translation products in each group of transcripts or translation products is performed.
claim 17
20. The method of wherein a comparison of at least ten of the transcripts or translation products in each group of transcripts or translation products is performed.
claim 17
21. The method of wherein a comparison of at least twenty of the transcripts or translation products in each group of transcripts or translation products is performed.
claim 17
22. The method of wherein a comparison of at least thirty of the transcripts or translation products in each group of transcripts or translation products is performed.
claim 17
23. The method of wherein a comparison of at leas fifty of the transcripts or translation products in each group of transcripts or translation products is performed.
claim 17
24. The method of wherein a comparison of at least seventy of the transcripts or translation products in each group of transcripts or translation products is performed.
claim 17
25. The method of wherein the level of expression of the RNA transcripts is determined using an array of nucleic acid molecules attached to a substrate in predetermined positions.
claim 1
26. The method of wherein the level of expression of the RNA transcripts is determined using an array of nucleic acid molecules attached to a substrate in predetermined positions.
claim 2
27. The method of wherein the level of expression of the RNA transcripts is determined using arrays of nucleic acid molecules attached to a substrate in predetermined positions.
claim 17
28. The method of wherein the level of expression of the RNA transcript is determined by a method comprising the steps of:
claim 1
harvesting sample mRNA from the samples;
reverse transcribing the sample mRNA to form DNA;
ligating a promoter to the DNA;
transcribing in vitro using the DNA as a template to form test mRNA;
hybridizing the test RNA to an array of nucleic acid molecules.
29. The method of wherein the level of expression of the RNA transcript is determined by a method comprising the steps of:
claim 2
harvesting sample mRNA from the samples;
reverse transcribing the sample mRNA to form DNA;
ligating a promoter to the DNA;
transcribing in vitro using the DNA as a template to form test mRNA;
hybridizing the test RNA to an array of nucleic acid molecules.
30. The method of wherein the level of expression of the RNA transcript is determined by a method comprising the steps of:
claim 17
harvesting sample mRNA from the samples;
reverse transcribing the sample mRNA to form DNA;
ligating a promoter to the DNA;
transcribing in vitro using the DNA as a template to form test mRNA;
hybridizing the test RNA to an array of nucleic acid molecules.
31. A method for evaluating carcinogenicity of an agent, comprising the steps of:
contacting a test agent with a human cell;
determining the level of expression of at least one transcript or its translation product in the human cell after contacting with the agent; wherein the transcript is of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2, wherein an agent which decreases the level of expression of a gene identified in FIG. 1, or an agent which increases the level of expression of a gene identified in FIG. 2 is a potential carcinogen.
32. The method of wherein determining the level of expression of at least two of the transcripts or translation products is performed.
claim 31
33. The method of wherein determining the level of expression of at least five of the transcripts or translation products is performed.
claim 31
34. The method of wherein determining the level of expression of at least ten of the transcripts or translation products is performed.
claim 31
35. The method of wherein determining the level of expression of at least twenty of the transcripts or translation products is performed.
claim 31
36. The method of wherein determining the level of expression of at least fifty of the transcripts or translation products is performed.
claim 31
37. The method of wherein determining the level of expression of 70 of the transcripts or translation products is performed.
claim 31
38. The method of wherein determining the level of expression of 90 of the transcripts or translation products is performed.
claim 31
39. The method of wherein determining the level of expression of 100 of the transcripts or translation products is performed.
claim 31
40. The method of wherein determining the level of expression of 125 of the transcripts or translation products is performed.
claim 31
41. The method of wherein determining the level of expression of 145 of the transcripts or translation products is performed.
claim 31
42. A method of treating cancer in a patient, comprising the step of:
administering to cancer cells of a patient a polynucleotide comprising a coding sequence of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1, wherein the cancer cells of the patient harbor a mutant p53 gene, whereby the gene is expressed in cells of the cancer.
43. A method of treating cancer in a patient, comprising the step of:
administering to cancer cells of a patient an antisense construct comprising at least 12 nucleotides of a coding sequence of a gene selected from the group consisting of genes numbered 7-24, and 26-100 in FIG. 2, wherein the coding sequence is in 3′ to 5′ orientation with respect to a promoter which controls its expression, wherein the cancer harbors a mutant p53 gene; whereby an antisense RNA is expressed in cells of the cancer.
44. A method of screening for drugs useful in the treatment of cancer, comprising:
contacting a cell which harbors a p53 mutation with a test substance;
monitoring expression of a transcript or its translation product, wherein the transcript is of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2, wherein a test substance is identified as a potential drug for treating cancer if it increases expression of a gene as shown in FIG. 1 or decreases expression of a gene as shown in FIG. 2.
45. A method of screening for drugs useful in the treatment of cancer, comprising:
contacting a tumor cell which overexpresses MDM2 with a test substance;
monitoring expression of a transcript or its translation product, wherein the transcript is of a gene selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2, wherein a test substance is identified as a potential drug for treating cancer if it increases expression of a gene as shown in FIG. 1 or decreases expression of a gene as shown in FIG. 2.
46. A set of at least two oligonucleotide probes which hybridize to a set of p53-regulated genes, wherein the genes are selected from the group consisting of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 26-100 in FIG. 2.
47. The set of which comprises five oligonucleotide probes.
claim 46
48. The set of which comprises ten oligonucleotide probes.
claim 46
49. The set of which comprises fifteen oligonucleotide probes.
claim 46
50. The set of which comprises twenty oligonucleotide probes.
claim 46
51. The set of which comprises twenty-five oligonucleotide probes.
claim 46
52. The set of which comprises thirty oligonucleotide probes.
claim 46
53. The set of which comprises fifty oligonucleotide probes.
claim 46
54. The set of which comprises seventy-five oligonucleotide probes.
claim 46
55. The set of which comprises 100 oligonucleotide probes.
claim 46
56. The set of which comprises 140 oligonucleotide probes.
claim 46
57. The set of wherein the probes are attached to a polymer.
claim 46
58. The set of wherein the probes are attached to a solid support.
claim 46
59. The set of which comprises probes which hybridize to each of genes numbered 1-8, 10, 12, 14-58, 60-68, and 70-100 in FIG. 1 and genes numbered 7-24, and 2&100 in FIG. 2.
claim 46
60. The set of wherein the probes are in a gel matrix.
claim 46
61. The set of wherein the probes are in solution.
claim 46
62. The set of wherein the probes are individually packaged in a single container.
claim 46
63. The set of wherein the probes are arrayed on a solid support.
claim 46
64. The method of wherein an immunoassay is performed to determine the level of expression.
claim 1
65. The method of wherein an immunoassay is performed to determine the level of expression.
claim 2
66. The method of wherein an immunoassay is performed to determine the level of expression.
claim 17
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/755,028 US20010039013A1 (en) | 1998-03-27 | 2001-01-08 | P53-regulated genes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/049,025 US6020135A (en) | 1998-03-27 | 1998-03-27 | P53-regulated genes |
US09/442,039 US6171798B1 (en) | 1998-03-27 | 1999-11-17 | P53-regulated genes |
US09/755,028 US20010039013A1 (en) | 1998-03-27 | 2001-01-08 | P53-regulated genes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/442,039 Division US6171798B1 (en) | 1998-03-27 | 1999-11-17 | P53-regulated genes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010039013A1 true US20010039013A1 (en) | 2001-11-08 |
Family
ID=21957674
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/049,025 Expired - Lifetime US6020135A (en) | 1998-03-27 | 1998-03-27 | P53-regulated genes |
US09/442,039 Expired - Lifetime US6171798B1 (en) | 1998-03-27 | 1999-11-17 | P53-regulated genes |
US09/755,028 Abandoned US20010039013A1 (en) | 1998-03-27 | 2001-01-08 | P53-regulated genes |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/049,025 Expired - Lifetime US6020135A (en) | 1998-03-27 | 1998-03-27 | P53-regulated genes |
US09/442,039 Expired - Lifetime US6171798B1 (en) | 1998-03-27 | 1999-11-17 | P53-regulated genes |
Country Status (9)
Country | Link |
---|---|
US (3) | US6020135A (en) |
EP (1) | EP1064404B1 (en) |
JP (1) | JP2002509732A (en) |
AT (1) | ATE269415T1 (en) |
AU (1) | AU3208599A (en) |
CA (1) | CA2324444A1 (en) |
DE (1) | DE69918072T2 (en) |
HK (1) | HK1038595A1 (en) |
WO (1) | WO1999050456A1 (en) |
Families Citing this family (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303301B1 (en) * | 1997-01-13 | 2001-10-16 | Affymetrix, Inc. | Expression monitoring for gene function identification |
US6355430B1 (en) * | 1998-12-24 | 2002-03-12 | Millennium Pharmaceuticals, Inc. | Diagnostic and screening methods employing KIAA0101 |
US6936424B1 (en) | 1999-11-16 | 2005-08-30 | Matritech, Inc. | Materials and methods for detection and treatment of breast cancer |
WO2001062965A2 (en) * | 2000-02-22 | 2001-08-30 | Oxford Biomedica (Uk) Limited | Differential expression screening method |
US6884578B2 (en) * | 2000-03-31 | 2005-04-26 | Affymetrix, Inc. | Genes differentially expressed in secretory versus proliferative endometrium |
EP1282699B1 (en) * | 2000-05-04 | 2012-11-21 | Sarepta Therapeutics, Inc. | Splice-region antisense composition and method |
US7700359B2 (en) * | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
EP1297186A4 (en) * | 2000-06-30 | 2005-06-29 | Univ Utah Res Found | Method of screening for chemotherapeutic treatments for cancer |
US7567870B1 (en) * | 2000-07-31 | 2009-07-28 | Institute For Systems Biology | Multiparameter analysis for predictive medicine |
DE10037769A1 (en) * | 2000-08-03 | 2002-02-21 | Epigenomics Gmbh | Diagnosis of diseases associated with CD24 |
US6713257B2 (en) * | 2000-08-25 | 2004-03-30 | Rosetta Inpharmatics Llc | Gene discovery using microarrays |
US7807447B1 (en) | 2000-08-25 | 2010-10-05 | Merck Sharp & Dohme Corp. | Compositions and methods for exon profiling |
US7108969B1 (en) * | 2000-09-08 | 2006-09-19 | Affymetrix, Inc. | Methods for detecting and diagnosing oral cancer |
GB0022978D0 (en) | 2000-09-19 | 2000-11-01 | Oxford Glycosciences Uk Ltd | Detection of peptides |
US6780594B2 (en) | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
DE10048633A1 (en) * | 2000-09-25 | 2002-04-18 | Schering Ag | Method for in vitro diagnosis of endometriosis |
US6743897B1 (en) | 2000-11-27 | 2004-06-01 | Cytokinetics, Inc. | Aspergillus fumigatus profilin |
US6403372B1 (en) | 2000-11-27 | 2002-06-11 | Cytokinetics, Inc. | Aspergillus fumigatus profilin |
WO2002099140A1 (en) * | 2001-06-05 | 2002-12-12 | Exelixis, Inc. | GLRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
ES2282444T3 (en) * | 2001-06-05 | 2007-10-16 | Auckland Uniservices Limited | METHOD AND COMPOSITIONS TO EVALUATE THE FUNCTION AND DISORDERS PULMO NARES. |
US6821737B2 (en) | 2001-06-08 | 2004-11-23 | Panomics, Inc. | Method for screening for drug candidates for modulating transcription factor activity |
US7981842B2 (en) | 2001-06-08 | 2011-07-19 | Panomics, Inc. | Method for detecting transcription factor-protein interactions |
US6924113B2 (en) | 2001-06-08 | 2005-08-02 | Panomics, Inc. | Method and kit for isolating DNA probes that bind to activated transcription factors |
US6696256B1 (en) | 2001-06-08 | 2004-02-24 | Pandmics, Inc. | Method, array and kit for detecting activated transcription factors by hybridization array |
US20040214166A1 (en) * | 2001-06-08 | 2004-10-28 | Xianqiang Li | Method for identifying a disease state based on a detected mixture of activated transcription factors |
US7343247B2 (en) * | 2001-07-30 | 2008-03-11 | The Institute For Systems Biology | Methods of classifying drug responsiveness using multiparameter analysis |
AU2002336410A1 (en) * | 2001-08-29 | 2003-09-09 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
US7781413B2 (en) * | 2001-10-31 | 2010-08-24 | Board Of Regents, The University Of Texas System | SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
US20030157700A1 (en) * | 2001-12-19 | 2003-08-21 | Affymetrix, Inc. | Apparatus and methods for constructing array plates |
US20030175713A1 (en) * | 2002-02-15 | 2003-09-18 | Clemens Sorg | Method for diagnosis of inflammatory diseases using CALGRANULIN C |
US20040096874A1 (en) * | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
US7504215B2 (en) | 2002-07-12 | 2009-03-17 | Affymetrix, Inc. | Nucleic acid labeling methods |
KR20060015446A (en) * | 2002-08-19 | 2006-02-17 | 윤 엔 | Treatment of liver diseases |
US8008003B2 (en) | 2002-11-15 | 2011-08-30 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
JP2006521793A (en) * | 2003-02-06 | 2006-09-28 | ゲノミック ヘルス, インコーポレイテッド | Gene expression marker responsive to EGFR inhibitor drug |
DE602004017426D1 (en) * | 2003-02-20 | 2008-12-11 | Genomic Health Inc | USE OF INTRONIC RNA SEQUENCES FOR THE QUANTIFICATION OF GENE EXPRESSION |
AU2004248140A1 (en) * | 2003-05-30 | 2004-12-23 | Cedars-Sinai Medical Center | Gene expression markers for response to EGFR inhibitor drugs |
CA3084542A1 (en) | 2003-06-10 | 2005-01-06 | The Trustees Of Boston University | Gene expression analysis of airway epithelial cells for diagnosing lung cancer |
ES2609234T3 (en) | 2003-06-24 | 2017-04-19 | Genomic Health, Inc. | Prediction of the probability of cancer recurrence |
EP1644858B1 (en) | 2003-07-10 | 2017-12-06 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
EP2182063A3 (en) * | 2003-09-18 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Modulation of EIF4E expression |
WO2005040396A2 (en) * | 2003-10-16 | 2005-05-06 | Genomic Health, Inc. | qRT-PCR ASSAY SYSTEM FOR GENE EXPRESSION PROFILING |
CA2551267C (en) * | 2003-12-23 | 2012-05-01 | Genomic Health, Inc. | Universal amplification of fragmented rna |
US20050191682A1 (en) | 2004-02-17 | 2005-09-01 | Affymetrix, Inc. | Methods for fragmenting DNA |
ES2381644T3 (en) | 2004-03-24 | 2012-05-30 | Tripath Imaging, Inc. | Methods and compositions for the detection of cervical diseases |
EP2163650B1 (en) | 2004-04-09 | 2015-08-05 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
US20060073506A1 (en) | 2004-09-17 | 2006-04-06 | Affymetrix, Inc. | Methods for identifying biological samples |
WO2006034278A2 (en) * | 2004-09-21 | 2006-03-30 | Matritech, Inc. | Methods and compositions for detecting cancer using components of the u2 spliceosomal particle |
US20060073511A1 (en) | 2004-10-05 | 2006-04-06 | Affymetrix, Inc. | Methods for amplifying and analyzing nucleic acids |
CA2584197A1 (en) * | 2004-10-14 | 2006-04-27 | Genentech, Inc. | Cop1 molecules and uses thereof |
CA2524964A1 (en) | 2004-10-29 | 2006-04-29 | Affymetrix, Inc. | Automated method of manufacturing polymer arrays |
US7682782B2 (en) | 2004-10-29 | 2010-03-23 | Affymetrix, Inc. | System, method, and product for multiple wavelength detection using single source excitation |
AU2005304878B2 (en) * | 2004-11-05 | 2010-07-08 | Genomic Health, Inc. | Molecular indicators of breast cancer prognosis and prediction of treatment response |
DK1836629T3 (en) | 2004-11-05 | 2020-05-18 | Genomic Health Inc | PREDICTION OF RESPONSE TO CHEMOTHERAPY USING MARKERS FOR GENEPRESSION |
US7957507B2 (en) | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
EP3770278A1 (en) | 2005-04-14 | 2021-01-27 | The Trustees of Boston University | Diagnostic for lung disorders using class prediction |
US20060269946A1 (en) * | 2005-05-10 | 2006-11-30 | Young Robert P | Methods and compositions for assessment of pulmonary function and disorders |
US8232535B2 (en) | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
JP5421590B2 (en) | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | Methods for diagnosis and treatment of diseases with autoimmune and / or inflammatory components |
CA2608158A1 (en) * | 2005-05-19 | 2006-11-23 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
KR20080011292A (en) * | 2005-05-19 | 2008-02-01 | 시너젠즈 바이오사이언스 리미티드 | Methods for the assessment of risk of developing lung cancer using analysis of genetic polymorphisms |
WO2006123943A1 (en) * | 2005-05-20 | 2006-11-23 | Synergenz Bioscience Limited | Methods of analysis of polymorphisms and uses thereof |
JP2009502253A (en) * | 2005-07-22 | 2009-01-29 | トモセラピー・インコーポレーテッド | System and method for applying radiation therapy to a moving region of interest |
EP1907984A4 (en) * | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | Method and system for processing data relating to a radiation therapy treatment plan |
US8442287B2 (en) | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
EP1907058B1 (en) * | 2005-07-22 | 2015-06-24 | TomoTherapy, Inc. | Method of placing constraints on a deformation map and system for implementing same |
KR20080049716A (en) | 2005-07-22 | 2008-06-04 | 토모테라피 인코포레이티드 | Method and system for evaluating quality assurance criteria in delivery of a treament plan |
JP2009502257A (en) * | 2005-07-22 | 2009-01-29 | トモセラピー・インコーポレーテッド | Method and system for evaluating delivered dose |
US8229068B2 (en) * | 2005-07-22 | 2012-07-24 | Tomotherapy Incorporated | System and method of detecting a breathing phase of a patient receiving radiation therapy |
JP2009502252A (en) * | 2005-07-22 | 2009-01-29 | トモセラピー・インコーポレーテッド | Method and system for adapting a radiation therapy treatment plan based on a biological model |
KR20080039920A (en) * | 2005-07-22 | 2008-05-07 | 토모테라피 인코포레이티드 | System and method of evaluating dose delivered by a radiation therapy system |
JP2009502254A (en) * | 2005-07-22 | 2009-01-29 | トモセラピー・インコーポレーテッド | Systems and methods for monitoring the operation of medical devices. |
JP5390855B2 (en) | 2005-07-23 | 2014-01-15 | トモセラピー・インコーポレーテッド | Imaging and delivery of radiation therapy using coordinated movement of gantry and treatment table |
WO2007028161A2 (en) * | 2005-09-02 | 2007-03-08 | The University Of Toledo | Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states |
WO2007044566A2 (en) * | 2005-10-07 | 2007-04-19 | Baylor Research Institute | Diagnosis of systemic onset juvenile idiopathic arthritis through blood leukocyte microarray analysis |
US7634363B2 (en) * | 2005-12-07 | 2009-12-15 | Affymetrix, Inc. | Methods for high throughput genotyping |
US7846664B2 (en) * | 2005-12-07 | 2010-12-07 | The Regents Of The University Of California | Diagnosis and treatment of chronic lymphocytic leukemia (CLL) |
EP1969506A1 (en) * | 2005-12-13 | 2008-09-17 | Erasmus University Medical Center Rotterdam | Genetic brain tumor markers |
MX2008009592A (en) | 2006-01-27 | 2008-09-08 | Tripath Imaging Inc | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor. |
EP2605018A1 (en) | 2006-03-09 | 2013-06-19 | The Trustees of the Boston University | Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells |
EP2389947A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
JP5244103B2 (en) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | Organ-specific protein and method of use thereof |
WO2008024114A1 (en) * | 2006-08-24 | 2008-02-28 | Genizon Biosciences Inc. | Genemap of the human genes associated with schizophrenia |
WO2008048986A2 (en) * | 2006-10-17 | 2008-04-24 | Children's Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
US9845494B2 (en) | 2006-10-18 | 2017-12-19 | Affymetrix, Inc. | Enzymatic methods for genotyping on arrays |
WO2008100352A2 (en) | 2006-11-03 | 2008-08-21 | Baylor Research Institute | Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis |
US8293684B2 (en) * | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
US8200440B2 (en) | 2007-05-18 | 2012-06-12 | Affymetrix, Inc. | System, method, and computer software product for genotype determination using probe array data |
EP2253713B1 (en) | 2008-03-11 | 2015-02-25 | National Cancer Center | Method for measuring chromosome, gene or specific nucleotide sequence copy numbers using snp array |
GB0809069D0 (en) | 2008-05-19 | 2008-06-25 | Univ Leuven Kath | Gene signatures |
SI2297359T1 (en) | 2008-05-30 | 2014-05-30 | The University Of North Carolina At Chapel Hill | Gene expression profiles to predict breast cancer outcomes |
ES2742251T3 (en) | 2009-03-16 | 2020-02-13 | Pangu Biopharma Ltd | Compositions and methods comprising variants of histidyl tarn synthetase splicing that have non-canonical biological activities |
CA2757289A1 (en) | 2009-03-31 | 2010-10-21 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities |
PL2488873T3 (en) | 2009-10-16 | 2016-01-29 | Novartis Ag | Biomarkers of tumor pharmacodynamic response |
US20120282276A1 (en) | 2009-11-05 | 2012-11-08 | The Regents Of The University Of Michigan | Biomarkers predictive of progression of fibrosis |
US8501122B2 (en) | 2009-12-08 | 2013-08-06 | Affymetrix, Inc. | Manufacturing and processing polymer arrays |
US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
EP2517020B1 (en) | 2009-12-23 | 2015-10-21 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating kidney disorders in a canine |
EA201201113A1 (en) | 2010-02-10 | 2013-03-29 | Новартис Аг | METHODS AND CONNECTIONS FOR GROWTH OF MUSCLE |
US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
WO2011139714A2 (en) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
CN103096911B (en) | 2010-04-27 | 2018-05-29 | Atyr 医药公司 | Treatment relevant with the protein fragments of Isoleucyl-tRNA synthetase, diagnosis and the innovation of antibody compositions are found |
WO2011139853A2 (en) | 2010-04-28 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
CN103097523B (en) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | The innovation for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Asparaginyl-tRNA synthetase finds |
WO2011150279A2 (en) | 2010-05-27 | 2011-12-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
AU2011248457B2 (en) | 2010-04-29 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases |
US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
CN105820252B (en) | 2010-05-03 | 2020-07-21 | Atyr 医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl- α -tRNA synthetases |
US8961961B2 (en) | 2010-05-03 | 2015-02-24 | a Tyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases |
CA2798139C (en) | 2010-05-04 | 2019-09-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
CN103200953B (en) | 2010-05-14 | 2017-02-15 | Atyr 医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
AU2011256366C1 (en) | 2010-05-17 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
WO2011150400A1 (en) * | 2010-05-28 | 2011-12-01 | New York Blood Center, Inc. | Nuclear scaffold protein stip/tfip11 target for cancer therapy |
EP2575857B1 (en) | 2010-06-01 | 2018-01-24 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
CA2800913C (en) | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
WO2011154139A2 (en) | 2010-06-07 | 2011-12-15 | Roche Diagnostics Gmbh | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
JP6047489B2 (en) | 2010-08-12 | 2016-12-21 | フェイト セラピューティクス,インコーポレイテッド | Improved hematopoietic stem and progenitor cell therapy |
CN103108650A (en) | 2010-08-25 | 2013-05-15 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases |
JP6163104B2 (en) | 2010-11-15 | 2017-07-12 | アクセラレイテッド・バイオサイエンシズ・コーポレーション | Generation of neural stem cells from human trophoblast stem cells |
EP2561102A1 (en) | 2010-12-02 | 2013-02-27 | Katholieke Universiteit Leuven K.U. Leuven R&D | Irak-related interventions and diagnosis |
EP3062108B1 (en) | 2011-02-24 | 2019-06-19 | Hill's Pet Nutrition, Inc. | Methods for diagnosing kidney disorders in a feline |
EP2680839A1 (en) | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
SG10201601224WA (en) | 2011-03-02 | 2016-03-30 | Berg Llc | Interrogatory cell-based assays and uses thereof |
EP2685988A4 (en) | 2011-03-15 | 2014-08-20 | Univ North Carolina | Methods of treating breast cancer with anthracycline therapy |
JP2014509515A (en) | 2011-03-18 | 2014-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Methods and compositions for predicting response to eribulin |
WO2012134813A1 (en) | 2011-03-31 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia |
US10144969B2 (en) | 2011-06-15 | 2018-12-04 | Colgate-Palmolive Company | Compositions and methods for diagnosing and monitoring hyperthyroidism in a feline |
CA2857597A1 (en) | 2011-11-30 | 2013-06-06 | AbbVie Deutschland GmbH & Co. KG | Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor |
CA2859149A1 (en) | 2011-12-19 | 2013-06-27 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating hyperthyroidism in companion animals |
EP3311847A1 (en) | 2012-02-16 | 2018-04-25 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
US11177020B2 (en) | 2012-02-27 | 2021-11-16 | The University Of North Carolina At Chapel Hill | Methods and uses for molecular tags |
CA2865575C (en) | 2012-02-27 | 2024-01-16 | Cellular Research, Inc. | Compositions and kits for molecular counting |
SG11201406201YA (en) | 2012-04-02 | 2014-10-30 | Berg Llc | Interrogatory cell-based assays and uses thereof |
AU2013243300B2 (en) | 2012-04-05 | 2018-12-06 | Oregon Health & Science University | Gene expression panel for breast cancer prognosis |
AU2013266419B2 (en) | 2012-05-22 | 2018-09-27 | British Columbia Cancer Agency Branch | NANO46 genes and methods to predict breast cancer outcome |
BR112015001690A2 (en) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutations associated with resistance to bruton tyrosine kinase inhibitors (btk) |
MX367366B (en) | 2012-11-27 | 2019-08-16 | Univ Pontificia Catolica Chile | Compositions and methods for diagnosing thyroid tumors. |
AU2013352307B2 (en) | 2012-11-30 | 2018-11-15 | Accelerated Biosciences Corp. | Methods of differentiating stem cells by modulating miR-124 |
WO2014113804A1 (en) | 2013-01-21 | 2014-07-24 | Abbvie Inc. | Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease |
EP2962309B1 (en) | 2013-02-26 | 2022-02-16 | Accuray, Inc. | Electromagnetically actuated multi-leaf collimator |
WO2014133855A1 (en) | 2013-02-28 | 2014-09-04 | Caprion Proteomics Inc. | Tuberculosis biomarkers and uses thereof |
EP3044332A1 (en) | 2013-09-09 | 2016-07-20 | British Columbia Cancer Agency Branch | Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy |
GB2534315B (en) | 2013-10-02 | 2020-08-05 | Univ Leland Stanford Junior | WNT compositions and methods for purification |
US10704097B2 (en) | 2014-02-27 | 2020-07-07 | Katholieke Universiteit Leuven | Oxidative stress and cardiovascular disease events |
DK3110973T3 (en) | 2014-02-27 | 2019-05-13 | Univ Leuven Kath | OXIDATIVE STRESS AND CARDIOVASCULAR DISEASES |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
JP2017516501A (en) | 2014-05-30 | 2017-06-22 | ジーンセントリック ダイアグノスティクス, インコーポレイテッド | Lung cancer typing method |
WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
US11610644B2 (en) | 2014-10-24 | 2023-03-21 | Koninklijke Philips N.V. | Superior bioinformatics process for identifying at risk subject populations |
JP7065609B6 (en) | 2014-10-24 | 2022-06-06 | コーニンクレッカ フィリップス エヌ ヴェ | Medical prognosis and prediction of therapeutic response using multiple cellular signaling pathway activities |
DK3210142T3 (en) | 2014-10-24 | 2020-11-16 | Koninklijke Philips Nv | ASSESSMENT OF TGF CELLULAR SIGNALING VEHICLE ACTIVITY USING MATHEMATICAL MODELING OF MOAL EXPRESSION |
CA3148687A1 (en) | 2014-11-26 | 2016-06-02 | Accelerated Biosciences Corp. | Induced hepatocytes and uses thereof |
AU2015360767A1 (en) | 2014-12-12 | 2017-06-08 | Medivation Prostate Therapeutics Llc | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
DK3234112T3 (en) | 2014-12-19 | 2020-03-02 | Univ Brussel Vrije | IN VITRO MATURING A MAMMAL-CUMULUS OOCYTE COMPLEX |
JP2016214239A (en) * | 2015-05-15 | 2016-12-22 | 国立大学法人高知大学 | Pancreatic cancer marker |
EP3328440A4 (en) | 2015-07-28 | 2019-01-16 | Otonomy, Inc. | Treatment using truncated trk b and trk c antagonists |
ES2861400T3 (en) | 2015-08-14 | 2021-10-06 | Koninklijke Philips Nv | Evaluation of the activity of the NFkB cell signaling pathway using mathematical models of target gene expression |
US20180305748A1 (en) | 2015-10-18 | 2018-10-25 | Affymetrix, Inc. | Multiallelic Genotyping of Single Nucleotide Polymorphisms and Indels |
KR20170076480A (en) | 2015-12-24 | 2017-07-04 | 삼성전자주식회사 | Composition including PINT gene expression inhibitor or activity inhibitor and use thereof |
WO2017176652A2 (en) | 2016-04-04 | 2017-10-12 | Sinopia Biosciences, Inc. | Treating extrapyramidal syndrome using trapidil |
CN109863251B (en) | 2016-05-17 | 2022-11-18 | 基因中心治疗公司 | Method for subtyping lung squamous cell carcinoma |
CA3024747A1 (en) | 2016-05-17 | 2017-11-23 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung adenocarcinoma |
EP3260552A1 (en) | 2016-06-20 | 2017-12-27 | Istituto Europeo di Oncologia (IEO) | Methods and kits comprising gene signatures for stratifying breast cancer patients |
WO2018013883A1 (en) | 2016-07-14 | 2018-01-18 | Caprion Proteomics Inc. | Biomarkers of latent tuberculosis infection |
EP3487874A1 (en) | 2016-07-20 | 2019-05-29 | Westfälische Wilhelms-Universität Münster | Complex-specific standardization of immunological methods for the quantification of s100a12 |
EP3655418A4 (en) | 2017-06-22 | 2021-05-19 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
US11739386B2 (en) | 2017-07-21 | 2023-08-29 | Genecentric Therapeutics, Inc. | Methods for determining response to PARP inhibitors |
WO2019067991A1 (en) | 2017-09-29 | 2019-04-04 | Triact Therapeutics, Inc. | Iniparib formulations and uses thereof |
EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
ES2960914T3 (en) | 2018-03-16 | 2024-03-07 | Gopath Laboratories Llc | Methods for personalized detection of cancer recurrence or metastasis and/or evaluation of response to treatment |
CN113166767A (en) | 2018-09-05 | 2021-07-23 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | Method for engineering synthesis of cis-regulated DNA |
CA3115922A1 (en) | 2018-10-09 | 2020-04-16 | Genecentric Therapeutics, Inc. | Detecting cancer cell of origin |
WO2020104482A1 (en) | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting metastatic potential in patients suffering from sdhb-mutated paraganglioma |
EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
EP3907301A1 (en) | 2020-05-08 | 2021-11-10 | Istituto Europeo di Oncologia S.r.l. | Methods and kits for determining the risk of breast cancer recurrence |
WO2023122758A1 (en) | 2021-12-22 | 2023-06-29 | Cornell University | Prognostic/predictive epigenetic breast cancer signature |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652115A (en) * | 1992-04-14 | 1997-07-29 | Duke University | Method of detecting tumors containing complexes of p53 and HSP70 |
US5667987A (en) * | 1994-07-12 | 1997-09-16 | Bristol-Myers Squibb Company | P53 response genes |
US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5702908A (en) * | 1994-07-20 | 1997-12-30 | University Of Dundee | Interruption of binding of MDM2 and p53 protein and therapeutic application thereof |
US5756669A (en) * | 1993-11-22 | 1998-05-26 | Onyx Pharmaceuticals, Inc. | P53-binding polypeptides and polynucleotides encoding same |
US5770377A (en) * | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
US5840673A (en) * | 1995-09-14 | 1998-11-24 | Bristol-Myers Squibb Company | Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of p53-related tumors |
US5858679A (en) * | 1992-11-12 | 1999-01-12 | Fornace, Jr.; Albert J. | Method for determining the presence of functional p53 by measuring GADD45 protein expression |
US5858976A (en) * | 1992-04-07 | 1999-01-12 | The Johns Hopkins University | Methods for inhibiting interaction of human MDM2 and p53 |
US6245886B1 (en) * | 1995-02-16 | 2001-06-12 | Bayer Corporation | Peptides and peptidomimetics with structural similarity to human P53 that activate P53 function |
US6297366B1 (en) * | 1998-01-14 | 2001-10-02 | Board Of Trustees Of The University Of Illinois | ING-encoded p33ING1 protein as a mediator of p53 signaling pathway in mammalian cells |
US6420136B1 (en) * | 1997-09-26 | 2002-07-16 | University Technologies International, Inc. | Method of modulating p53 activity |
US6432640B1 (en) * | 1997-09-17 | 2002-08-13 | The Johns Hopkins University | P53-induced apoptosis |
US6479285B1 (en) * | 1997-07-02 | 2002-11-12 | Board Of Regents, The University Of Texas System | p53 as a regulator of cell differentiation |
US6492116B1 (en) * | 1995-09-18 | 2002-12-10 | Cancer Research Campain Technology Ltd. | Assay for identifying inhibitors of the interaction between proteins p53 and dm2 |
US6645944B2 (en) * | 1992-04-06 | 2003-11-11 | Alton Ochsner Medical Foundation | Inhibition of cellular proliferation by oligonucleotide binding to a chromosomal binding site for p53 protein |
US6649353B2 (en) * | 1997-08-14 | 2003-11-18 | Wolfgang Willi Deppert | Method for influencing the p53 linkage to target genes |
US6696441B1 (en) * | 2000-08-11 | 2004-02-24 | The Regents Of The University Of California | Inhibition of p53-induced stress response |
US6770474B2 (en) * | 1998-10-16 | 2004-08-03 | Deutsches Krebsforschungszentrum | p53 binding areas |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8810400D0 (en) * | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
DE69032864T3 (en) * | 1989-03-29 | 2013-01-31 | The Johns Hopkins University | Evidence of failure of the wild-type p53 gene |
EP0931830B1 (en) * | 1993-02-16 | 2001-03-07 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and phophylaxis of neoplasia |
WO1995019369A1 (en) * | 1994-01-14 | 1995-07-20 | Vanderbilt University | Method for detection and treatment of breast cancer |
AU8382998A (en) * | 1997-07-02 | 1999-01-25 | Genzyme Corporation | P53 influenced gene expression |
-
1998
- 1998-03-27 US US09/049,025 patent/US6020135A/en not_active Expired - Lifetime
-
1999
- 1999-03-26 JP JP2000541343A patent/JP2002509732A/en active Pending
- 1999-03-26 WO PCT/US1999/006656 patent/WO1999050456A1/en active IP Right Grant
- 1999-03-26 EP EP99914184A patent/EP1064404B1/en not_active Expired - Lifetime
- 1999-03-26 DE DE69918072T patent/DE69918072T2/en not_active Expired - Lifetime
- 1999-03-26 CA CA002324444A patent/CA2324444A1/en not_active Abandoned
- 1999-03-26 AU AU32085/99A patent/AU3208599A/en not_active Abandoned
- 1999-03-26 AT AT99914184T patent/ATE269415T1/en not_active IP Right Cessation
- 1999-11-17 US US09/442,039 patent/US6171798B1/en not_active Expired - Lifetime
-
2001
- 2001-01-08 US US09/755,028 patent/US20010039013A1/en not_active Abandoned
- 2001-06-11 HK HK01103999A patent/HK1038595A1/en not_active IP Right Cessation
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US6645944B2 (en) * | 1992-04-06 | 2003-11-11 | Alton Ochsner Medical Foundation | Inhibition of cellular proliferation by oligonucleotide binding to a chromosomal binding site for p53 protein |
US5858976A (en) * | 1992-04-07 | 1999-01-12 | The Johns Hopkins University | Methods for inhibiting interaction of human MDM2 and p53 |
US5652115A (en) * | 1992-04-14 | 1997-07-29 | Duke University | Method of detecting tumors containing complexes of p53 and HSP70 |
US5858679A (en) * | 1992-11-12 | 1999-01-12 | Fornace, Jr.; Albert J. | Method for determining the presence of functional p53 by measuring GADD45 protein expression |
US5756669A (en) * | 1993-11-22 | 1998-05-26 | Onyx Pharmaceuticals, Inc. | P53-binding polypeptides and polynucleotides encoding same |
US5667987A (en) * | 1994-07-12 | 1997-09-16 | Bristol-Myers Squibb Company | P53 response genes |
US5886149A (en) * | 1994-07-12 | 1999-03-23 | Bristol-Myers Squibb Co. | P53 response genes |
US5702908A (en) * | 1994-07-20 | 1997-12-30 | University Of Dundee | Interruption of binding of MDM2 and p53 protein and therapeutic application thereof |
US5770377A (en) * | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
US6245886B1 (en) * | 1995-02-16 | 2001-06-12 | Bayer Corporation | Peptides and peptidomimetics with structural similarity to human P53 that activate P53 function |
US5840673A (en) * | 1995-09-14 | 1998-11-24 | Bristol-Myers Squibb Company | Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of p53-related tumors |
US6492116B1 (en) * | 1995-09-18 | 2002-12-10 | Cancer Research Campain Technology Ltd. | Assay for identifying inhibitors of the interaction between proteins p53 and dm2 |
US6479285B1 (en) * | 1997-07-02 | 2002-11-12 | Board Of Regents, The University Of Texas System | p53 as a regulator of cell differentiation |
US6649353B2 (en) * | 1997-08-14 | 2003-11-18 | Wolfgang Willi Deppert | Method for influencing the p53 linkage to target genes |
US6432640B1 (en) * | 1997-09-17 | 2002-08-13 | The Johns Hopkins University | P53-induced apoptosis |
US6420136B1 (en) * | 1997-09-26 | 2002-07-16 | University Technologies International, Inc. | Method of modulating p53 activity |
US6297366B1 (en) * | 1998-01-14 | 2001-10-02 | Board Of Trustees Of The University Of Illinois | ING-encoded p33ING1 protein as a mediator of p53 signaling pathway in mammalian cells |
US6770474B2 (en) * | 1998-10-16 | 2004-08-03 | Deutsches Krebsforschungszentrum | p53 binding areas |
US6696441B1 (en) * | 2000-08-11 | 2004-02-24 | The Regents Of The University Of California | Inhibition of p53-induced stress response |
Also Published As
Publication number | Publication date |
---|---|
HK1038595A1 (en) | 2002-03-22 |
EP1064404B1 (en) | 2004-06-16 |
WO1999050456A1 (en) | 1999-10-07 |
ATE269415T1 (en) | 2004-07-15 |
JP2002509732A (en) | 2002-04-02 |
CA2324444A1 (en) | 1999-10-07 |
US6171798B1 (en) | 2001-01-09 |
US6020135A (en) | 2000-02-01 |
DE69918072T2 (en) | 2005-07-07 |
EP1064404A1 (en) | 2001-01-03 |
DE69918072D1 (en) | 2004-07-22 |
AU3208599A (en) | 1999-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1064404B1 (en) | P53-regulated genes | |
US6727066B2 (en) | Genes expressed in treated human C3A liver cell cultures | |
US6682890B2 (en) | Methods of diagnosing and determining prognosis of colorectal cancer | |
US20050266442A1 (en) | Immortalized human Tuberous Sclerosis null angiomyolipoma cell and method of use thereof | |
US20020156263A1 (en) | Genes expressed in breast cancer | |
KR20110020853A (en) | Methods of diagnosing rejection of a kidney allograft using genomic or proteomic expression profiling | |
EP1546409A2 (en) | Method for diagnosing chronic myeloid leukemia | |
US20030165924A1 (en) | Genes expressed in foam cell differentiation | |
US20030065157A1 (en) | Genes expressed in lung cancer | |
US20150232948A1 (en) | Method of Detecting and Treating Tuberous Sclerosis Complex Associated Disorders | |
JP2008503212A (en) | Methods for diagnosis and treatment of obesity, diabetes and insulin resistance | |
US20050170500A1 (en) | Methods for identifying risk of melanoma and treatments thereof | |
JP2001524311A (en) | Methods for identifying the toxic / pathological effects of environmental irritants on gene transcription | |
US20110236396A1 (en) | Methods and compositions for diagnosing and treating a colorectal adenocarcinoma | |
EP1560025A2 (en) | Specific markers for diabetes | |
US20110151469A1 (en) | Interferon epsilon (ifne1) as a marker for targeted cancer therapy | |
KR20060087977A (en) | Markers for the diagnosis of lung cancer | |
US6544742B1 (en) | Detection of genes regulated by EGF in breast cancer | |
US20030119009A1 (en) | Genes regulated by MYCN activation | |
EP1693452B1 (en) | Method of estimating toxicity of drug | |
CA2323932A1 (en) | Methods for identifying anti-cancer agents | |
US20050079496A1 (en) | Methods for diagnosing and treating neoplasias using nf-at transcriptions factors | |
US20100129790A1 (en) | Method for Determining Phospholipidosis | |
Waisfisz et al. | Analysis of baseline and cisplatin-inducible gene expression in Fanconi anemia cells using oligonucleotide-based microarrays | |
JP4819791B2 (en) | Method for determining phospholipidosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |